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Abstract
Background: Klotho was originally characterized as an anti-aging gene that predisposed Klotho-deficient mice to a 
premature aging-like syndrome. Recently, KLOTHO was reported to function as a secreted Wnt antagonist and as a 
tumor suppressor. Epigenetic gene silencing of secreted Wnt antagonists is considered a common event in a wide 
range of human malignancies. Abnormal activation of the canonical Wnt pathway due to epigenetic deregulation of 
Wnt antagonists is thought to play a crucial role in cervical tumorigenesis. In this study, we examined epigenetic 
silencing of KLOTHO in human cervical carcinoma.
Results: Loss of KLOTHO mRNA was observed in several cervical cancer cell lines and in invasive carcinoma samples, 
but not during the early, preinvasive phase of primary cervical tumorigenesis. KLOTHO mRNA was restored after 
treatment with either the DNA demethylating agent 2'-deoxy-5-azacytidine or histone deacetylase inhibitor 
trichostatin A. Methylation-specific PCR and bisulfite genomic sequencing analysis of the promoter region of KLOTHO 
revealed CpG hypermethylation in non-KLOTHO-expressing cervical cancer cell lines and in 41% (9/22) of invasive 
carcinoma cases. Histone deacetylation was also found to be the major epigenetic silencing mechanism for KLOTHO in 
the SiHa cell line. Ectopic expression of the secreted form of KLOTHO restored anti-Wnt signaling and anti-clonogenic 
activity in the CaSki cell line including decreased active β-catenin levels, suppression of T-cell factor/β-catenin target 
genes, such as c-MYC and CCND1, and inhibition of colony growth.
Conclusions: Epigenetic silencing of KLOTHO may occur during the late phase of cervical tumorigenesis, and 
consequent functional loss of KLOTHO as the secreted Wnt antagonist may contribute to aberrant activation of the 
canonical Wnt pathway in cervical carcinoma.
Background
Cervical carcinoma is the second most common cause of
cancer death in women worldwide [1]. Several epidemio-
logical studies have indicated that the human papilloma-
virus (HPV) provides the 'initial hit' in the development
o f  c e r v i c a l  c a n c e r  [ 2 ] .  I t  h a s  b e e n  h y p o t h e s i z e d  t h a t
deregulation of the canonical Wnt signaling pathway is
the 'second hit' in the multistep process of cervical car-
cinogenesis [3,4]. Aberrant activation of the Wnt/β-
catenin signaling pathways has been regarded as a generic
pathway in a variety of human malignancies [5,6]. Gain-
of-function mutations centered in the N-terminus of
CTNNB1  (encoding the β-catenin gene) induced these
oncogenic proteins to be refractory to proteosomal deg-
radation in many tumors. Although cytoplasmic/nuclear
accumulation of β-catenin is frequently found in the
malignant uterine cervix, this increase in β-catenin is not
associated with a mutation in exon 3 of CTNNB1 [7]. Pre-
vious studies have revealed that epigenetic gene silencing
of soluble Wnt antagonists, such as secreted Frizzled-
related proteins (SFRPs), constitutes one of the major
alterations resulting in constitutive activation of the
canonical Wnt pathway in many tumors, particularly col-
orectal [8], bladder [9], gastric [10], and breast cancer
[11]. In addition, abnormal CpG island methylation of
key tumor suppressor genes has been reported in invasive
cervical cancer [12]. We therefore examined whether pro-
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moter methylation of the genes encoding secreted Wnt
antagonists is responsible for stabilization of β-catenin
levels in cervical carcinoma.
Klotho has been characterized as systemic anti-aging
hormone [13] and was originally identified in mice
homozygous for the mutated allele (kl-/-). These mice
show a human-like aging-related syndrome and develop
multiple disorders such as hypogonadism, ectopic calcifi-
cation, osteoporosis, skin atrophy, and pulmonary
emphysema. Klotho-deficient mice die around 8-9 weeks
of age [14]. In contrast, transgenic mice overexpressing
Klotho have an extended life span that is 30% longer in
males and 20% longer in females [15]. KLOTHO encodes
a single-pass type-1 transmembrane protein as well as a
truncated, secreted form derived from alternative RNA
splicing. The major transcript in humans produces the
secreted form, and the extracellular domain of the mem-
brane-bound form is shed and then secreted. These solu-
b l e  K L O T H O  p r o d u c t s  f u n c t i o n  a s  c i r c u l a t i n g  f a c t o r s
that are involved in multiple signaling pathways.
Although the molecular mechanism of Klotho in the sup-
pression of aging-related phenotypes is unknown, Klotho
was shown to be a secreted antagonist of the Wnt signal-
ing pathway [16]. Klotho inhibits Wnt signaling activity
by forming a complex with Wnt3, which is a manner of
the SFRP class of secreted Wnt antagonists. Recently,
KLOTHO was identified as a potential tumor suppressor
that inhibits the IGF-1 pathway and activates the FGF
pathway in human breast cancer [17]. In this study, we
hypothesized that KLOTHO encoding the secreted Wnt
antagonist and that acts as a tumor suppressor may be a
candidate target for epigenetic silencing in human cervi-
cal carcinoma.
Results and Discussion
Transcriptional repression of KLOTHO in human cervical 
cancer
To investigate epigenetic gene silencing of the SFRP class
of secreted Wnt antagonists in human cervical carci-
noma, we first examined the mRNA levels of SFRP1,
SFRP2, SFRP4, SFRP5, and KLOTHO  in eight cervical
cancer cell lines (Figure 1A). RT-PCR analysis showed
complete loss of SFRP mRNAs in the CaSki, HeLa, and
SNU-1299 cell lines and overall transcriptional downreg-
ulation of SFRPs in these cervical cancer cell lines. Com-
plete transcriptional silencing of SFRP1,  SFRP2  and
SFRP5 was recently reported to be associated with pro-
moter methylation in the CaSki and HeLa cell lines [18].
Although the SNU-703 and SNU-1160 cell lines
expressed substantial levels of KLOTHO mRNA, loss of
expression was found in the CaSki and SNU-1299 cell
lines. In contrast with the SiHa and SNU-17 cell lines,
which had extremely low levels of KLOTHO mRNA, the
HeLa cell line showed a basal level of KLOTHO expres-
sion. To examine whether the transcriptional repression
of KLOTHO also occurs in primary cervical tumors, we
performed RT-PCR for KLOTHO in 4 samples of low-
grade squamous intraepithelial lesion (LSIL), 6 samples of
high-grade squamous intraepithelial lesion (HSIL), and
10 samples of invasive carcinoma (Figure 1B). It was pre-
viously reported that the expression of KLOTHO was pre-
dominant in the placenta, kidney, small intestine, and
prostate [19]. cDNAs prepared from human placenta and
normal cervical epithelial tissues were used as positive
controls. Four of the ten invasive cervical carcinoma sam-
ples showed complete loss of KLOTHO  expression,
whereas maintenance of KLOTHO mRNA was observed
in all of the early, preinvasive lesions (LSILs and HSILs).
Thus, KLOTHO is downregulated in human cervical can-
cer cell lines and in invasive cervical carcinoma.
To determine whether the loss of KLOTHO expression
is associated with epigenetic gene silencing, we used RT-
PCR to examine transcriptional reactivation in represen-
tative cell lines lacking KLOTHO mRNA following treat-
ment with either the DNA methyltransferase (DNMT)
inhibitor 2'-deoxy-5-azacytidine (DAC) or the histone
deacetylase (HDAC) inhibitor trichostatin A (TSA) (Fig-
ure 1C). DNA demethylation by DAC induced significant
restoration of KLOTHO mRNA expression in the SNU-
1299 cell line, but incomplete upregulation was seen in
the SiHa cell line. When each cell line was treated with
TSA alone, KLOTHO restoration was detected only in the
SiHa cell line. A synergistic effect of DAC and TSA was
observed in the SNU-1299 cell line, in which the
KLOTHO mRNA was restored only with a DNA demeth-
ylating drug. Taken together, these data imply that the
downregulation of KLOTHO in cervical cancer cell lines
is correlated with epigenetic inactivation mechanisms
involving DNA methylation and histone deacetylation.
Promoter CpG hypermethylation of KLOTHO in cervical 
cancer
To analyze the methylation status of the CpG islands in
the KLOTHO promoter region, methylation-specific PCR
(MSP) and bisulfite genomic sequencing (BGS) analysis
were performed in cervical cancer cell lines. As shown in
Figure 2A, a dense GC-rich region was identified around
the transcription start site of KLOTHO. Positive controls
for unmethylated alleles were verified with MSP using
genomic DNA from human placenta. Positive controls for
methylated alleles were confirmed by MSP of in vitro
methylated DNA (IVD) of the same material. Unmethy-
lated (U) products were predominant in the promoter
region of control DNA from human placenta; however,
methylated (M) products were exclusively amplified from
an IVD template (Figure 2B). The promoter methylation
profile obtained from the MSP analysis of KLOTHO rep-
resented a complete methylation pattern in the CaSki,Lee et al. Molecular Cancer 2010, 9:109
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SNU-17, and SNU-1299 cell lines. In contrast, the SNU-
703 and SNU-1160 cell lines showed an unmethylated
KLOTHO promoter region. These results were consistent
with the RT-PCR analysis: the KLOTHO-expressing cell
lines SNU-703 and SNU-1160 exhibited unmethylated
promoter CpGs, and the non-KLOTHO-expressing cell
lines CaSki, SNU-17, and SNU-1299 showed methylated
CpGs. To further determine the methylation density of
the  KLOTHO promoter region, which encompasses 54
CpGs, we performed a BGS analysis of the cervical cancer
Figure 1 Transcriptional repression of KLOTHO is associated with epigenetic inactivation in cervical cancer. A, RT-PCR analysis showing mRNA 
expression of the secreted Frizzled-related protein (SFRP) class of secreted Wnt antagonists in cervical cancer cell lines. Overall downregulation of SFRPs 
and variable mRNA levels of KLOTHO (KL) were detected. ACTB (encoding β-actin) is shown as an internal control. B, The KLOTHO mRNA expression 
pattern in primary cervical tumor samples. cDNAs prepared from human placenta (Plc) and from normal (N) cervical tissue were used as positive con-
trols for KLOTHO expression. C, Transcriptional restoration of KLOTHO by either the DNMT inhibitor DAC or the HDAC inhibitor TSA in representative 
non-KLOTHO-expressing cell lines.Lee et al. Molecular Cancer 2010, 9:109
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Figure 2 Hypermethylation of the promoter region of KLOTHO in cervical cancer. A, Schematic representation of the upstream region of 
KLOTHO around the transcription start site (+1) and the primer location. The vertical lines represent the CpG dinucleotides. B, MSP assay of KLOTHO in 
cervical cancer cell lines. In vitro methylated DNA (IVD) from a placenta was used as a positive control for methylated DNA. C, Representative results 
of the MSP analysis of KLOTHO in human cervical tissue samples. Normal, LSIL, HSIL, and invasive carcinoma represent the histopathologic grades of 
cervical carcinogenesis.Lee et al. Molecular Cancer 2010, 9:109
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Figure 3 Bisulfite genomic sequencing analysis of the KLOTHO promoter region in cervical cancer. Each row of circles represents the DNA se-
quence of individual clones. The open and filled circles represent the unmethylated and methylated CpG sites, respectively. Partial methylation in the 
HeLa cell line was detected.Lee et al. Molecular Cancer 2010, 9:109
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cell lines (Figure 3). Although extensive hypermethylation
of the KLOTHO promoter region was prominent in the
cell lines that lacked KLOTHO expression (CaSki, SNU-
17, and SNU-1299), the KLOTHO-expressing cell lines
(SNU-703 and SNU-1160) tended to have completely
unmethylated CpG islands. These data strongly suggest
that transcriptional repression of KLOTHO is associated
with aberrant promoter hypermethylation in cervical
cancer cell lines.
We next examined the methylation status of primary
cervical tumor samples to investigate whether KLOTHO
undergoes abnormal methylation in association with the
histopathologic grades of squamous intraepithelial
lesions (Figure 2C). Promoter methylation was not
detected in the normal cervical samples (n = 7), the LSIL
(n = 30) or the HSIL (n = 37), but extensive methylation
was observed exclusively in nine of 22 (41%) of the inva-
sive carcinoma cases. Based on these observations, the
number of non-KLOTHO-expressing tissue samples (Fig-
ure 1B) may be consistent with the methylation frequency
of primary cervical tumors. To confirm the MSP results,
we carried out bisulfite sequencing analysis using repre-
sentative cases, including two normal and two invasive
carcinoma samples (Figure 3). The overall methylation of
the KLOTHO promoter region in the invasive carcinoma
cases was in good agreement with the MSP data, whereas
a fully unmethylated pattern was observed in the normal
samples. Thus, epigenetic silencing of KLOTHO due to
promoter hypermethylation may occur in an invasive car-
cinoma phase-specific manner during cervical carcino-
genesis.
Histone deacetylation is the major epigenetic silencing 
mechanism for KLOTHO in the SiHa cell line
A chromatin immunoprecipitation (ChIP) assay using
anti-acetyl histone H3 (AcH3) and H4 (AcH4) antibodies
was performed to determine whether SiHa cells utilize
local histone modification as a mechanism of KLOTHO
silencing. The immunoprecipitated DNA was analyzed
by PCR to elucidate the histone H3 and H4 acetylation
level of the KLOTHO promoter region. Figure 2A shows
the promoter region around the transcription start site
(+1) that was analyzed by the ChIP assay. As shown in
Figure 4, marked differences were observed between the
acetylation level of histones H3 and H4 in untreated SiHa
cells. Although very low levels of PCR products were
detected in the control SiHa cells, TSA treatment
resulted in a dramatic amplification of specific DNA frag-
ments immunoprecipitated with the AcH3 antibody. This
result suggested that the KLOTHO promoter is enriched
in deacetylated histone H3, leading to repressive histone
modification in the SiHa cell line. On the other hand, the
acetylation level of histone H4 seemed to not be associ-
ated with restoration of KLOTHO mRNA after treatment
with TSA in the SiHa cell line. Suzuki et al. reported that
a group of genes lacking promoter CpG methylation
tended to be reactivated after HDAC inhibition alone
[20]. Our study identified unmethylated CpGs present in
the KLOTHO promoter in the SiHa cell line (Figure 3).
Thus, deacetylated histone H3 in the promoter region is
strongly correlated with epigenetic silencing of KLOTHO
in the SiHa cell line.
KLOTHO functions as a secreted Wnt antagonist in cervical 
cancer
To assess whether KLOTHO inhibits the Wnt signaling
pathway in cervical cancer, the CaSki cell line was trans-
fected with a cDNA expression vector that produces a
secreted form of KLOTHO (pcDNA3.1/V5-His-sKL).
Ectopic expression of sKL protein resulted in a decrease
in total β-catenin levels and a dramatic reduction in the
active form of β-catenin (ABC), which is dephosphory-
lated on S37 or T41 residues (Figure 5A). The expression
of representative T-cell factor (TCF)/β-catenin target
genes, including c-MYC  and  CCND1  (encoding Cyclin
D1), was markedly decreased in the CaSki cell line when
the overexpression of sKL was induced (Figure 5B). c-
MYC is a specific oncogene that is commonly activated
during cervical carcinogenesis [21]. These findings indi-
cate that the canonical Wnt pathway is inhibited by a
secreted form of KLOTHO in a cervical cancer cell line.
Finally, we performed a colony formation assay to test the
tumor-suppressor activity of KLOTHO as a result of inhi-
bition of Wnt/β-catenin signaling. As shown in Figure
5C, CaSki cells transfected with the sKL expression vec-
tor showed 57% fewer colonies compared to the empty
vector. This result shows that KLOTHO functions as a
potential tumor suppressor and that loss of KLOTHO
may contribute to cervical carcinogenesis.
Abnormal activation of the canonical Wnt pathway due
to epigenetic deregulation of Wnt antagonists is thought
to play a crucial role during multi-step cervical tumori-
Figure 4 ChIP analysis of the KLOTHO promoter region in SiHa 
cells. Antibodies against acetylated histone H3 (AcH3) and H4 (AcH4) 
were used to isolate acetylated chromatin fragments from lysates of 
control and TSA-treated SiHa cells, respectively. DNA fragments corre-
sponding to the KLOTHO promoter around the transcription start site 
were amplified by PCR.Lee et al. Molecular Cancer 2010, 9:109
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genesis. In addition, several extracellular antagonists of
the Wnt pathway, including SFRP1, SFRP2 [18], DKK1
[22], and DKK3 [23], were reported to be downregulated
by methylation in cervical cancer. Baylin et al. proposed
that epigenetic changes may cause cancer cells to become
"addicted" to altered signaling pathways, e.g., the Wnt/β-
catenin pathway, during the early stages of tumorigenesis
[24]. These early epigenetic events that occur in the
secreted Wnt-antagonist gene family may allow these
cells, i.e., HPV-infected cervical epithelial cells, to acquire
genetic or epigenetic alterations in the same pathway,
providing the cell with selective advantages that promote
tumor development. In our unpublished studies, frequent
epigenetic inactivation of the SFRP  gene family was
observed during the early, preinvasive phase of cervical
carcinogenesis preceding KLOTHO silencing. Our results
suggest that loss of KLOTHO during the late phase may
be another important step toward invasion of cervical
cancer cells with aberrant Wnt signaling. Our current
study shows that KLOTHO is frequently downregulated
both in cervical cancer cell lines and in invasive carcino-
mas of the primary cervical tumors and that transcrip-
Figure 5 Inhibition of the Wnt/β-catenin pathway and colony growth following ectopic expression of the secreted form of KLOTHO (sKL) 
in a cervical cancer cell line. A, Immunoblot analysis of KLOTHO, total β-catenin, and active β-catenin (ABC) in CaSki cells transfected with either the 
sKL expression vector or the empty vector. B, RT-PCR analysis of TCF/β-catenin target genes, i.e., c-MYC and CCND1, in CaSki cells transfected with either 
the sKL expression vector or the empty vector. ACTB is shown as an internal control. C, Colony formation assay showing that restoration of KLOTHO 
suppresses tumor cell growth in the CaSki cell line.Lee et al. Molecular Cancer 2010, 9:109
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tional repression of KLOTHO  is associated with
promoter hypermethylation. We show here that epige-
netic aberrations of KLOTHO  occurred in an invasive
carcinoma phase-specific manner and that a loss of func-
tion of KLOTHO induced oncogenic activation of TCF/
β-catenin target genes in a cervical carcinoma. Thus, epi-
genetic aberrations of the secreted Wnt antagonist
KLOTHO may contribute to the development of cervical
cancer. Our analysis is the first to establish that KLOTHO,
the gene for a secreted Wnt-antagonist undergoes epige-
netic silencing in human cancers. It remains to be deter-
mined whether KLOTHO is epigenetically inactivated in
other types of human cancer. Moreover, KLOTHO may be
a potential target for the treatment of invasive carcino-
mas and as a prognostic biomarker of cervical cancer.
Conclusions
This study suggests that transcriptional repression of
KLOTHO is correlated with promoter CpG hypermethy-
lation in cervical cancer. Frequent (41%) promoter meth-
ylation of KLOTHO occurred in invasive carcinoma but
not in normal cervical tissues or during the early, preinva-
sive phase of primary cervical tumors. Our study also
showed that histone deacetylation was responsible for
silencing of KLOTHO in the SiHa cell line. Functional loss
of KLOTHO due to epigenetic silencing may contribute
to aberrant activation of the canonical Wnt pathway in
cervical carcinoma.
Methods
Cell culture and drug treatment
The human cervical cancer cell line C-33A was obtained
from the American Type Culture Collection (Manassas,
VA), and CaSki, HeLa, SiHa, SNU-17, SNU-703, SNU-
1160, and SNU-1299 were obtained from the Korean Cell
Line Bank (Seoul, Korea) [25]. The C-33A and CaSki cell
lines were derived from carcinomas, SiHa and all the
SNU-series cell lines were derived from squamous cell
carcinomas, and the HeLa cell line was derived from an
adenocarcinoma. The HPV-negative cell line C-33A, the
HPV-16-positive cell line SiHa, and the HPV-18-positive
cell line HeLa were grown in Dulbecco's Modified Eagle
Medium (Invitrogen) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, and 250 ng/ml amphotericin B. The HPV-16-positive
cell lines CaSki, SNU-17, SNU-703, and SNU-1299, and
the HPV-18-positive cell line SNU-1160 were grown in
RPMI-1640 medium (Invitrogen) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100 μg/ml strep-
tomycin, and 250 ng/ml amphotericin B. All cells were
maintained at 37°C in a humidified incubator with 5%
CO2. We treated the cervical cancer cell lines with DAC
(Sigma) for 72 h and TSA (Sigma) for 24 h.
Tissue samples and nucleic acid preparation
The uterine cervical tissues were obtained either by
punch biopsy or hysterectomy from patients with cervical
intraepithelial neoplasm. The tissues were fixed in 10%
neutral buffered formalin for 6 to 12 h, and then embed-
ded in paraffin. The histopathologic diagnoses of tissues
were made by a pathologist. All patients provided
informed consent, and the study was approved by the
institutional review board of Soonchunhyang University
Cheonan Hospital. After identification of the uterine cer-
vical epithelial lesions on hematoxylin and eosin-stained
slides, a pathologist manually dissected the epithelial por-
tions with a 26 gauge needle using a light microscope and
added the cells to lysis buffer (10 mM Tris-HCl, pH 8.0;
0.1 mM EDTA, pH 8.0; 2% SDS; 0.15 mg proteinase K).
Samples were incubated at 60°C until they were com-
pletely lysed, and then genomic DNA was extracted with
phenol:chloroform:isoamyl alcohol (25:24:1) and ethanol
precipitated at -20°C overnight. The DNA pellet was then
dissolved and quantified using a NanoDrop® ND-1000
Spectrophotometer (Nanodrop Technologies, USA).
After the same tissue samples were treated with lysis buf-
fer at 55°C for 3 h, total RNA was extracted using TRIzol
Reagent (Invitrogen) according to the manufacturer's
protocol.
Reverse transcription-PCR
Total RNA was isolated from cell lines using an RNeasy
Mini kit (Qiagen) following the manufacturer's instruc-
tions, and cDNA synthesis was performed with 1 μg of
the total RNA using the ImProm-II™ Reverse Transcrip-
tion System (Promega). The primer sequences for RT-
PCR of the KLOTHO cDNA were 5'-ACTCCCCCAGT-
CAGGTGGCGGTA-3' (forward) and 5'-TGGGCCCGG-
GAAACCATTGCTGTC-3' (reverse). All amplifications
were carried out with AccuPower PCR PreMix (Bioneer).
Human  ACTB  (encoding β-actin) was amplified as an
endogenous control.
Methylation analysis
Genomic DNA was extracted from cell lines using a
DNeasy Tissue kit (Qiagen), and bisulfite modification of
genomic DNA was performed using an EZ DNA Methy-
lation kit (Zymo Research), following the manufacturers'
instructions. Bisulfite-converted genomic DNA was
amplified using specific MSP primer sets that discrimi-
nate between unmethylated (U) and methylated (M) pro-
moter region of KLOTHO. The sequences of the U-
specific primer set were 5'-AGAGGATGTGTGGTAGG-
TAAAGAG-3' (forward) and 5'-ACAAACCAAAAC-
TACCTCCACCCT-3' (reverse). The sequences of the M-
specific primer set for the M1 region were 5'-AGAG-
GACGCGCGGTAGGTAA-3' (forward) and 5'-
ACGAACCGAAACTACCTCCGC-3' (reverse). WeLee et al. Molecular Cancer 2010, 9:109
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treated the human placental DNA with SssI methylase
(New England Biolabs) following the manufacturer's pro-
tocol for use as positive control for methylation analysis.
Bisulfite genomic sequencing was performed to deter-
mine the methylation density of the 357 bp fragment con-
taining 54 CpGs at the 5'-end region of KLOTHO. The
primer sequences were 5'-GGGAGTTGGGA-
GAAATAGGTGT-3' (forward) and 5'-CCAAACCCAA-
CAACACCAACAAC-3' (reverse). PCR products were
purified and subcloned into the pGEM-T Easy Vector
(Promega) for subsequent sequencing analysis.
Chromatin immunoprecipitation analysis
ChIP analysis was carried out using an EZ ChIP kit (Milli-
pore) following the manufacturer's protocol. SiHa cells (4
× 105 cells) were plated in a 100-mm culture dish and
incubated for 24 h. Formaldehyde-treated cells were
resuspended in SDS lysis buffer, and the cell lysates were
sheared by sonication. The chromatin fragments were
immunoprecipitated with antibodies against acetylated
histone H3 (Millipore) or H4 (Millipore), and then the
purified DNA was analyzed by PCR using the primer
pairs: 5'-AGTCCCGGCTCGCAGGTAATTATTG-3'
(forward) and 5'-AGGAGGCCGCGAGAAACGGG-3'
(reverse), which were designed to amplify nucleotides -
134 to +155 of KLOTHO.
Transfection, immunoblotting, and colony formation assay
T h e  s e c r e t e d  f o r m  o f  h u m a n  KLOTHO  (sKL) cDNA
cloned into pcDNA3.1/V5-His expression vector (Invit-
rogen) was a generous gift from Michael J. Econs (Indiana
University School of Medicine, Indianapolis, IN, USA).
CaSki cells were plated at 1 × 106 cells/60- mm culture
dish 24 h prior to transfection and were transfected with
5 μg of either the sKL expression vector or an empty con-
trol vector for 5 h in serum-free medium using Lipo-
fectamine 2000 (Invitrogen). After replacing the DNA-
Lipofectamine complex-containing medium with com-
plete growth medium, transfected cells were incubated
for 72 h. For immunoblotting, 20 μg of protein per lane
were separated on polyacrylamide gels and blotted onto
PVDF membranes (Millipore). Antibodies against
KLOTHO (Santa Cruz), total β-catenin (Cell Signaling),
and active β-catenin (Millipore) were used to probe the
blot. For the colony formation assay, CaSki cells were
plated in 6-well plates after transfection and selected with
1 mg/ml G418 (Invitrogen) for 17 d. Subsequently, colo-
nies were stained with crystal violet, and duplicate wells
were counted.
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